Interventional Radiology – Independent
College
- Center City Campus
- Sidney Kimmel Medical College
Degree Earned
- Residency
Program Length
2 years
Program Type
- On Campus
Leadership
Name:
Robert Adamo, MD
Position:
Program Director, Interventional Radiology Residency Programs, Integrated & Independent
Email:
Robert.Adamo@jefferson.edu
Name:
Stephen R. Topper, MD
Position:
Assistant Program Director, Interventional Radiology Residency Programs, Integrated & Independent
Email:
Stephen.Topper@jefferson.edu
Program Information
Name:
Sofiane Moulla
Position:
Education Coordinator, Radiology Residency Programs
Email:
Sofiane.Moulla@jefferson.edu
Contact Number(s):
Virtual Interview Dates
Thursday, November 7, 2024
Friday, November 8, 2024
Thursday, November 21, 2024
Thursday, December 5, 2024
Friday, December 6, 2024
Thursday, December 19, 2024
Curriculum
Interventional Radiology curriculum includes:
- Didactic lectures weekly
- Dedicated IR clinic – Daily
- Multidisciplinary conference – Metastatic Uveal Melanoma (MUM), Hepatocellular Carcinoma (HCC), Dialysis access conference.
- Multidisciplinary Clinic – Metastatic Uveal Melanoma (MUM), Hepatocellular Carcinoma (HCC), Small Renal Mass Clinic (SRMC), coming soon Uterine Fibroid clinic.
- MUM & HCC clinics established over a decade ago, SRMC >5 years
- Non-invasive vascular imaging (CT-A, MRA, vascular ultrasound (Radiology Run!!)
- Journal Club
- Mortality & Morbidity conference
- Grand Rounds
- Numerous clinical research opportunities
- National conferences (SIR, WCIO, SIR Fellows Practicum)
Uveal Melanoma Program
- Metastatic Uveal Melanoma is an “Orphan Disease” that has Found a home at Jefferson.
- Jefferson is a National & International referral center for metastatic uveal melanoma (MUM)
- Three quarters of our patients live outside of PA, DE and NJ.
- Multidisciplinary team includes Medical Oncology, Radiation Oncology, and Interventional Radiology
- 650 embolization procedures/year performed on MUM patients
- Numerous clinical trials
- One such trial is the Phase 3, multicenter trial (Delcath PHP-OCM-301 study)